Chr del(13q) + Chr del(11q) + SF3B1 mutation	Chronic Lymphocytic Leukemia	Chr del(13q) + Chr del(11q) + SF3B1 mutation	Chronic Lymphocytic Leukemia	umbralisib Resistant: D – Preclinical umbralisib Resistant : D	umbralisib Resistant: D – Preclinical umbralisib Resistant : D
Chr del(13q) + Chr del(11q) + SF3B1 mutation	Chronic Lymphocytic Leukemia	Chr del(13q) + Chr del(11q) + SF3B1 mutation	Chronic Lymphocytic Leukemia	duvelisib Resistant: D – Preclinical duvelisib Resistant : D	duvelisib Resistant: D – Preclinical duvelisib Resistant : D
Chr del(13q) + Chr del(11q) + SF3B1 mutation	Chronic Lymphocytic Leukemia	Chr del(13q) + Chr del(11q) + SF3B1 mutation	Chronic Lymphocytic Leukemia	idelalisib Resistant: D – Preclinical idelalisib Resistant : D	idelalisib Resistant: D – Preclinical idelalisib Resistant : D

Chr del(13q) + Chr del(11q) + SF3B1 mutation

Associations